- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05104931
PK Evaluation of a Nanoformed Oral IR Piroxicam Tablet in Healthy Subjects
A Phase 1, Single-Centre, Part-Crossover, OpenLabel, Partially-Randomised Study Designed to Evaluate the PK Profile of Piroxicam Following Administration of Nanoformed Oral IR Piroxicam Tablet and an IR Reference Product in Healthy Subjects
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a single-centre, open-label, partly-randomised, part-cross-over up to three-period, comparative bioavailability study in healthy male and female subjects, designed to investigate the pharmacokinetic (PK) properties and safety of Nanoformed Piroxicam Immediate Release (IR) Tablet, 5 - 20 mg and Felden® (piroxicam) Tablets 20 mg (reference) with an optional Brexidol® (piroxicam) Tablets 20 mg (alternative reference; optional in Period 3. Subjects will receive single oral doses of the investigational medicinal product across up to 3 treatment periods in either the fasted or fed state (optional in Period 3 only). Subjects will be randomised to 1 of 2 treatment sequences across Periods 1 and 2 which will be dosed in the fasted state. Following completion of Period 2, there will be an interim analysis of the PK and safety data generated from both previous periods to decide whether to proceed to an optional Period 3 and, if progression is made, to dose the Nanoformed Piroxicam IR Tablet, 5 - 20 mg in the fed state, an alternative dose level of Nanoformed Piroxicam IR Tablet, 5 - 20 mg in the fasted state or an alternative reference product in the fasted state in Period 3 (optional). The maximum dose of piroxicam that will be administered in any period of the study is 20 mg. For Period 3, if the Nanoformed Piroxicam IR Tablet, 5 - 20 mg formulation is selected, the dose will be selected from a bracketing dose range of 5 to 20 mg. Each period will follow the same study design. There will be a minimum washout of 12 days between each product administration. It is expected that the study will be executed in a single group, requiring a total of 3 study periods.
The study is exploratory and no formal sample size calculation has been made. Based on experience from previous studies of a similar design, a total of 12 subjects are to be enrolled and a minimum of 8 evaluable subjects are considered sufficient.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Nottingham, United Kingdom, NG11 6JS
- Quotient Sciences
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy males or non-pregnant, non-lactating healthy females
- Aged 18 to 55 years inclusive at the time of signing informed consent
- Body mass index (BMI) of 18.0 to 32.0 kg/m2 as measured at screening
- Must be willing and able to communicate and participate in the whole study
- Must provide written informed consent
- Must agree to adhere to the contraception requirements
Exclusion Criteria:
- Subjects who have received any IMP in a clinical research study within the 90 days prior to Day 1
- Subjects who are, or are immediate family members of, a study site or sponsor employee
- Evidence of current SARS-CoV-2 infection
- History of any drug or alcohol abuse in the past 2 years
- Regular alcohol consumption in males >21 units per week and females >14 units per week (1 unit = ½ pint beer, or a 25 mL shot of 40% spirit, 1.5 to 2 Units = 125 mL glass of wine, depending on type)
- A confirmed positive alcohol breath test at screening or admission
- Current smokers and those who have smoked within the last 12 months. A positive urine cotinine test at screening or admission
- Current users of e-cigarettes and nicotine replacement products and those who have used these products within the last 12 months
- Females who are pregnant or lactating (all female subjects must have a negative urine pregnancy test)
- Subjects who do not have suitable veins for multiple venepunctures/cannulation as assessed by the investigator or delegate at screening
- Clinically significant abnormal clinical chemistry, haematology or urinalysis as judged by the investigator
- Confirmed positive drugs of abuse test result
- Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) antibody results
- History of clinically significant cardiovascular (including ischaemic heart disease, peripheral arterial disease, heart failure), renal, hepatic, dermatological, chronic respiratory (including asthma) or neurological or psychiatric disorder, as judged by the investigator
- History of gastro-intestinal ulceration, bleeding or perforation
- History of gastrointestinal disorders that predispose to bleeding disorders such as ulcerative colitis, Crohn's disease, gastrointestinal cancers or diverticulitis
- Subjects with active peptic ulcer, inflammatory gastrointestinal disorder or gastrointestinal bleeding
- Subjects with a history of cholecystectomy or gall stones
- History of adverse reactions or allergy associated with any drug
- Serious adverse reaction or serious hypersensitivity to any drug or the formulation excipients
- History of previous serious allergic drug reaction of any type, especially cutaneous reactions such as erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis
- Previous skin reaction (regardless of severity) to piroxicam, other NSAIDs and other medications
- Subjects in whom aspirin and other NSAIDs induce the symptoms of asthma, nasal polyps, angioedema or urticaria
- Presence or history of clinically significant allergy requiring treatment, as judged by the investigator. Hay fever is allowed unless it is active
- Donation of blood or plasma within the previous 3 months or loss of greater than 400 mL of blood
- Subjects who are taking, or have taken, any prescribed or over-the-counter drug or herbal remedies (other than up to 4 g of paracetamol per day or hormonal replacement therapy [HRT]/hormonal contraception) in the 14 days before IMP administration. Exceptions may apply on a case by case basis, if considered not to interfere with the objectives of the study, as determined by the investigator
- Concomitant use of other NSAIDs, including cyclooxygenase-2 inhibitors, selective NSAIDs and acetylsalicylic acid at analgesic doses
- Failure to satisfy the investigator of fitness to participate for any other reason
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Nanoformed Piroxicam IR Tablet
orally delivered nanoformed piroxicam immediate release tablets (20mg)
|
Orally delivered Nanoformed Piroxicam
Other Names:
|
Active Comparator: Felden (piroxicam) Tablets
orally delivered Felden (piroxicam) tablets (20mg)
|
orally delivered Felden (reference) tablets
Other Names:
|
Active Comparator: Brexidol (piroxicam) Tablets
orally delivered Brexidol (piroxicam) tablets (20mg)
|
Orally delivered Nanoformed Piroxicam
Other Names:
orally delivered Brexidol (reference) tablets
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To determine the Maximum Plasma Concentration (Cmax) of piroxicam following administration of single oral doses of Nanoformed Piroxicam IR Tablet 5 - 20 mg and Felden (piroxicam) Tablets 20mg (reference) in healthy subjects in the fasted state.
Time Frame: 72 hours
|
To determine the pharmacokinetics and relative bioavailability of piroxicam over a 72h period following administration of single oral doses of Nanoformed Piroxicam IR Tablet 5 - 20 mg and Felden (piroxicam) Tablets 20mg (reference) in healthy subjects in the fasted state by determining the Maximum Plasma Concentration (Cmax).
|
72 hours
|
To determine the Area Under the drug Concentration of piroxicam following administration of single oral doses of Nanoformed Piroxicam IR Tablet 5 - 20 mg and Felden (piroxicam) Tablets 20mg (reference) in healthy subjects in the fasted state.
Time Frame: 72 hours
|
To determine the pharmacokinetics and relative bioavailability of piroxicam over a 72h period following administration of single oral doses of Nanoformed Piroxicam IR Tablet 5 - 20 mg and Felden (piroxicam) Tablets 20mg (reference) in healthy subjects in the fasted state by determining the Area Under the drug Concentration time curve over 1 hour (AUC(0 1h)), AUC from time 0 to the time of last measurable concentration (AUC(0 last)) and AUC from time 0 extrapolated to infinity (AUC(0-inf)).
|
72 hours
|
To determine the time to Cmax (Tmax) of piroxicam following administration of single oral doses of Nanoformed Piroxicam IR Tablet 5 - 20 mg and Felden (piroxicam) Tablets 20mg (reference) in healthy subjects in the fasted state.
Time Frame: 72 hours
|
To determine the pharmacokinetics and relative bioavailability of piroxicam over a 72h period following administration of single oral doses of Nanoformed Piroxicam IR Tablet 5 - 20 mg and Felden (piroxicam) Tablets 20mg (reference) in healthy subjects in the fasted state by determining the time to Cmax (Tmax).
|
72 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants that report adverse events (AEs) coded using MedDRA v23.1, pre-dose and 48-72h post-dose, for determining safety and tolerability.
Time Frame: 72 hours
|
To assess additional safety and tolerability information for piroxicam following administration of single oral doses of Nanoformed Piroxicam IR Tablet, 5 - 20mg in healthy subjects by assessing and reporting adverse events (AEs)
|
72 hours
|
To assess additional safety and tolerability information for piroxicam following administration of single oral doses of Nanoformed Piroxicam IR Tablet, 5 - 20mg in healthy subjects by assessing and reporting supine electrocardiograms
Time Frame: 72 hours
|
To assess and report 12 lead supine electrocardiogram-measured P-wave pre-dose and 48-72h post-dose, for determining safety and tolerability.
|
72 hours
|
To assess additional safety and tolerability information for piroxicam following administration of single oral doses of Nanoformed Piroxicam IR Tablet, 5 - 20mg in healthy subjects by assessing and reporting supine electrocardiograms
Time Frame: 72 hours
|
To assess and report 12 lead supine electrocardiogram-measured QT Interval pre-dose and 48-72h post-dose, for determining safety and tolerability.
|
72 hours
|
To assess additional safety and tolerability information for piroxicam following administration of single oral doses of Nanoformed Piroxicam IR Tablet, 5 - 20mg in healthy subjects by assessing and reporting supine electrocardiograms
Time Frame: 72 hours
|
To assess and report 12 lead supine electrocardiogram-measured QRS Complex pre-dose and 48-72h post-dose, for determining safety and tolerability.
|
72 hours
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Philip Evans, MBChB, Quotient Sciences
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Piroxicam
Other Study ID Numbers
- Unicorn
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pain
-
Flowonix MedicalApproved for marketingBack Pain | Leg Pain | Trunk Pain | Intractable Pain | Arm Pain
-
University Hospital Schleswig-HolsteinZealand University Hospital; European Regional Development Fund; Design School...CompletedPain, Acute | Pain, Chronic | Pain Measurement | Pain, CancerGermany
-
Dow University of Health SciencesRecruitingLow Back Pain | Chronic Low-back Pain | Low Back Pain, Mechanical | Mechanical Low Back Pain | Pain, Chronic | Pain, Back | Lower Back Pain Chronic | CLBP - Chronic Low Back PainPakistan
-
Dr. Negrin University HospitalCompletedPostoperative Pain, Acute | Postoperative Pain, ChronicSpain
-
George Washington UniversityRecruitingCervical Fusion | Pain, Back | Pain, Neck | Myofacial PainUnited States
-
Universitat Jaume ICompletedPain, Acute | Pain, Chronic | OncologySpain
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingPostoperative Pain | Postoperative Pain, Acute | Postoperative Pain, Chronic | VATSTurkey
-
Janssen Research & Development, LLCCompletedPain, Radiating | Pain, Burning | Pain, Crushing | Pain, Migratory | Pain, SplittingUnited States, France, Spain, Poland, Portugal
-
susanne beckerSNSFCompletedLow Back Pain | Pain, Acute | Pain, ChronicSwitzerland
-
University of Campinas, BrazilCompletedPREGNANCY | LUMBAR BACK PAIN | PELVIC PAIN
Clinical Trials on Nanoformed Piroxicam IR Tablet
-
Janssen Research & Development, LLCCompleted
-
MapLight TherapeuticsEnrolling by invitationAutism Spectrum DisorderUnited States, Australia
-
Stallergenes GreerCompleted
-
Stallergenes GreerCompletedPrimary DiseaseFrance, Italy, Spain
-
Stallergenes GreerCompletedAllergic Rhinitis Due to Grass PollensUnited States
-
GlaxoSmithKlineCompleted
-
Stallergenes GreerCompleted
-
AlexionRecruiting
-
Stallergenes GreerCompletedSeasonal Allergic RhinitisAustria
-
Daewon Pharmaceutical Co., Ltd.Completed